Skip to Content
Biotechnology and health

The US government wants to speed gene-editing therapies to patients

January 24, 2018

The National Institutes of Health wants to help researchers cure inherited diseases using genome-editing technology.

New funding: The US biomedical research agency says it is dedicating $190 million over the next six years to researchers conducting gene-editing experiments, such as those with the powerful CRISPR technique.

The background: As the US moves closer to using CRISPR in humans, NIH is making special funds available as a way to “dramatically accelerate the translation of these technologies to the clinic for treatment of as many genetic diseases as possible,” says director Francis Collins.

No designer babies: NIH is only accepting proposals for studies that involve making edits to human somatic cells, the nonreproductive cells of the body. By law, the agency is forbidden from funding research that involves modifying embryos, which would result in edited DNA being passed down to the next generation.

Deep Dive

Biotechnology and health

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

An AI-driven “factory of drugs” claims to have hit a big milestone

Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology

The quest to legitimize longevity medicine

Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.

There is a new most expensive drug in the world. Price tag: $4.25 million

But will the latest gene therapy suffer the curse of the costliest drug?

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.